Axogen (AXGN) Insider Burke William Mr. Buys 14,150 Shares

Burke William, a significant insider at Axogen, Inc. (NasdaqCM: AXGN), bought 14,150 shares on June 19, 2026. The total value of the transaction was not disclosed. This purchase adds to a recent wave of insider buying at the company, which has seen confidence from multiple executives.

Inside Burke William's Trade

Burke William increased his holdings by acquiring 14,150 shares. This move follows several other recent insider purchases at Axogen, including transactions by Alan Levine and John Johnson, who each bought 4,392 shares on June 24, 2026. This pattern of purchases may indicate a positive outlook among insiders.

Other Institutional Activity in Axogen

Several institutional players have made adjustments to their positions in Axogen. Blackrock Inc. increased its stake by 548,482 shares, bringing its total to 4,419,208 shares valued at approximately $153.8 million. Meanwhile, Morgan Stanley trimmed its holdings by 375,072 shares, ending with 2,747,924 shares worth about $95.7 million. First Light Asset Management reduced its position by 1,254,495 shares, now holding 2,748,361 shares valued at around $95.7 million.

Axogen, Inc. Stock Up 1.0%

As of today, Axogen's shares are trading at $44.69, slightly above its previous close of $44.23. The stock has shown strong performance, nearing its 52-week high of $52.91. It's important to note that the stock's price is well above its 50-day moving average of $45.28, suggesting positive momentum in the market.

Recent Earnings

In its latest earnings report, Axogen reported revenue of $251.2 million, a growth of 23.1% year-over-year. However, the company posted a net loss with an EPS of -0.67. The next earnings release is scheduled for October 28, 2026, which may provide more insights into its financial performance.

Insider Buying and Selling at Axogen, Inc.

Alongside Burke William, several insiders participated in recent buying activity. On June 24, 2026, Alan Levine, John Johnson, and Burke William each bought 4,392 shares, demonstrating a shared confidence among the leadership even as financial performance remains under scrutiny.

Analysts Set New Price Targets

Analysts have recently shown a positive outlook for Axogen. On October 12, 2026, B of A Securities initiated coverage with a Buy rating and a price target of $52. On October 7, Barclays also initiated coverage with an Overweight rating and a target of $55. The consensus price target among analysts stands at $53.9 based on ten opinions.

About Axogen, Inc.

Axogen, Inc. focuses on developing technologies for repairing peripheral nerves. The company operates in the healthcare sector and is headquartered in Alachua, Florida. Its innovative solutions aim to improve outcomes for patients undergoing nerve repair procedures, making it a notable player in the medical devices industry.

Bottom Line

With several insiders increasing their stakes, Axogen, Inc. is attracting attention. Watch for the upcoming earnings report on October 28, 2026, as it will be crucial for understanding the company’s ongoing performance. Remember that this insider buying reflects past positions and may not indicate current holdings.